Woebot Well being scores $9.5M and extra digital well being fundings

Date:

Share post:



Woebot Well being, maker of an AI-powered psychological well being chatbot, introduced Tuesday it has raised $9.5 million from Leaps by Bayer.

The strategic funding comes about eight months after the corporate stated it had scored $90 million in Collection C funding. Final 12 months, Woebot acquired FDA Breakthrough System Designation for its digital therapeutic treating postpartum despair.

“Woebot Well being’s mission and merchandise are properly aligned with our leaps quantity 5 and 10 to guard the mind and the thoughts, and to rework well being with information,” Dr. Jürgen Eckhardt, head of Leaps by Bayer, stated in a press release.

“With its deep deal with medical proof and distinctive AI-based platform and merchandise, Woebot Well being is forging a brand new frontier in behavioral well being at a crucial time in our world. We’re excited to help endeavors that can make tech-supported steady care a actuality for all.”

Based in 2017, Woebot places its complete elevate at $123.5 million.


OpenLoop, which offers staffing and help to digital well being corporations launching digital care providers, scooped up $8 million in Collection A funding. 

The spherical was led by SpringTide Ventures with participation from ManchesterStory, Subsequent Degree Ventures, Panoramic Ventures, ISA Ventures and a few strategic healthcare syndicates. OpenLoop stated the Collection A brings its complete elevate to about $11 million. 

The startup presents regulatory and authorized help, supplier staffing, telehealth infrastructure, administrative providers and income cycle administration to corporations constructing out digital care providers. It says it should use the funding to develop its tech infrastructure and rent new staffers for its follow administration and income cycle groups.


Prescription digital therapeutic firm metaMe Well being raised $2.2 million in a bridge funding spherical led by Hyde Park Angels with participation from particular person traders.

The corporate will use the funding to arrange for the market launch of Regulora, a prescription digital therapeutic geared toward treating stomach ache related to irritable bowel syndrome in adults. The therapeutic acquired FDA 510(okay) clearance late final 12 months. metaMe stated it plans to launch Regulora within the second half of 2022.

“We’re thrilled to have the help of HPA as we put together for the launch of Regulora,” CEO Tim Rudolphi stated in a press release. “We imagine that Regulora is poised to alter the lives of the tens of millions of Individuals who are suffering from IBS. HPA’s help offers the capital and experience we have to put together for launch and lift our Collection A funding.”



Supply hyperlink

LEAVE A REPLY

Please enter your comment!
Please enter your name here

spot_img

Related articles

Rethink New 12 months’s Resolutions ► Newbie Exercise Plans For 2023

Each New 12 months’s, the message is at all times the identical: “do higher, in much less...

Impartial MP Zoe Daniel requires higher consuming dysfunction funding

We commend and thank Zoe Daniel and fellow federal impartial members for shining a nationwide highlight on...

Operating Sneakers Are on Main Sale at Nordstrom Proper Now

Initially $320, now $240 Out there sizes: 5-11 (in half sizes, choose offered out) When the...